RT Journal Article
SR Electronic
T1 Surface sampling for SARS-CoV-2 in workplace outbreak settings in the UK, 2021-22
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.17.23286079
DO 10.1101/2023.02.17.23286079
A1 Nicholls, Ian
A1 Spencer, Antony
A1 Chen, Yiqun
A1 Bennett, Allan
A1 Atkinson, Barry
YR 2023
UL http://medrxiv.org/content/early/2023/02/23/2023.02.17.23286079.abstract
AB Aims To utilise environmental surface sampling to evaluate areas of SARS-CoV-2 contamination within workplaces to identify trends and improve local COVID-control measures.Methods and Results Surface sampling was undertaken at 12 workplaces that experienced a cluster of COVID-19 cases in the workforce between March 2021 and March 2022. 7.4% (61/829) of samples collected were positive for SARS-CoV-2 RNA by qPCR with only 1.8% (15/829) of samples identified with crossing threshold (Ct) values below 35.0. No sample returned whole genome sequence inferring RNA detected was degraded.Conclusions Few workplace surface samples were positive for SARS-CoV-2 RNA and positive samples typically contained low levels of nucleic acid. Although these data may infer a low probability of fomite transmission or other forms of transmission within the workplace, Ct values may have been lower at the time of contamination. Workplace environmental sampling identified lapses in COVID-control measures within individual sites and showed trends through the pandemic.Significance and Impact of the Study Prior to this study, few published reports investigated SARS-CoV-2 RNA contamination within workplaces experiencing cases of COVID-19. This report provides extensive data on environmental sampling identifying trends across workplaces and through the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding from the PROTECT COVID-19 National Core Study on Transmission and Environment, managed by the Health and Safety Executive on behalf of HM Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COVID-OUT study has been approved by the NHS North East Research Ethics Committee (Reference 20/NE/0282).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript